AstraZeneca plc (ADR)  

(Public, NYSE:AZN)   Watch this stock  
Find more results for AZN
31.31
+0.01 (0.03%)
Mar 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 31.10 - 31.38
52 week 25.55 - 35.04
Open 31.19
Vol / Avg. 3.98M/4.99M
Mkt cap 78.10B
P/E 22.65
Div/yield 0.95/4.47
EPS 1.38
Shares 1.27B
Beta 0.89
Inst. own 27%
Feb 2, 2017
Full Year 2016 AstraZeneca PLC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 32.53% 14.81%
Operating margin 45.35% 21.31%
EBITD margin - 31.23%
Return on average assets 11.59% 5.56%
Return on average equity 52.91% 20.99%
Employees 59,700 -
CDP Score - 97 B

Address

Cambridge Biomedical Campus 1 Francis Crick Avenue
LONDON, CB2 0AA
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Officers and directors

Pascal Soriot Executive Director and Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Marc Dunoyer Executive Director, Chief Financial Officer
Age: 63
Bio & Compensation  - Reuters
Fiona Cicconi Executive Vice-President, Human Resources
Bio & Compensation  - Reuters
Sean Bohen M.D., Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Pam P. Cheng Executive Vice President - Operations and Information Technology
Age: 45
Bio & Compensation  - Reuters
Ruud Dobber Executive Vice President, Europe
Bio & Compensation  - Reuters
Paul Hudson President, AstraZeneca, US and Executive Vice-President, North America
Bio & Compensation  - Reuters
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Bio & Compensation  - Reuters
Mark Mallon Executive Vice President, International
Bio & Compensation  - Reuters
Luke Miels Executive Vice-President, Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs
Bio & Compensation  - Reuters